IXICO plc announced the following changes to the Board, all of which take immediate effect: Dr. Andy Richards has elected to step down from the Board to focus on his other commitments. Andy has been Chairman of the company since 2009 and has guided the company through its formative years. Charles Spicer has succeeded Andy as Non-Executive Chairman. Charles was an executive Director of the company between July 2013 and January 2016 with a focus on corporate strategy. He became a Non-Executive Director of the company in January 2016. He has a wealth of experience working for, and as advisor to, public and private companies primarily in the medtech and life science sectors. Charles is currently Chairman of an NIHR Invention for Innovation (i4i) funding panel and is also Non-Executive Chairman of PuriCore Plc, 11 Health & Technologies Limited and Creo Medical Limited. In addition, Mark Warne joins the Board as a Non-Executive Director. He is Head of the Healthcare division of IP Group Plc. Mark previously acted as the power of attorney for corporate director IP2IPO Services Limited of Optimal Medicine Limited and was instrumental in the sale of the business to IXICO. Mark brings a wealth of technology commercialization experience to support IXICO through its next stage of product development and value creation. Mark will join the Remuneration Committee which is chaired by Tim Sharpington and the Audit Committee which is chaired by John Bradshaw. David Brister, who joined the Board following the acquisition of Optimal Medicine Limited, stepped down as a Non-Executive Director having helped oversee the successful integration of this acquisition.